Blood Vessels are tubes through which the blood circulates in the body. Blood vessels include a network of arteries, arterioles, capillaries, venules, and veins.
Diabetes causes more new cases of legal blindness among working-age Americans than any other disease. If diabetics are monitored regularly by their ophthalmologist, this vision loss is almost always avoidable. Yet, tragically, more than half of all people living with diabetes do not get the recommended annual dilated eye exam. As the number of people with Type 2 diabetes rises in the U.S., the CDC projects that the number of adults with diabetic retinopathy will double by the year 2050. Yet 90 percent of diabetic eye disease can be prevented simply by proper regular examinations and treatment and by controlling blood sugar.
Canada urgently needs to focus on prevention of vascular diseases to avoid the burden from the expected tsunami of cases, says noted stroke expert Dr. Robert Côté, delivering the Heart and Stroke Foundation of Canada (HSFC) Lecture at the Canadian Cardiovascular Congress 2010.
TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that new data on TRC105 and TRC102 will be presented at the 22nd Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.
A toxin found in the venom of the Central American bark scorpion (Centruroides margaritatus) could hold the key to reducing heart bypass failures, according to research from the University of Leeds.
Researchers from Mount Sinai School of Medicine, in collaboration with investigators of the National Institute of Health and Medical Research (INSERM) of France led by Nicolae Ghinea, PhD, have found a common link among several malignant tumor types in all grades of cancer. This breakthrough may ultimately provide a new diagnostic or therapeutic target to detect cancer early or stop tumor growth.
A latest study shows that a hormone receptor normally confined to the reproductive organs is found in malignant tumors in many parts of the body. Researchers from the Mt. Sinai School of Medicine in New York City explained that this may mean a new target for the early diagnosis and treatment of cancer. The study was published in the latest issue of The New England Journal of Medicine.
MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal™ BioStent.
At the American Academy of Ophthalmology (AAO) Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting today, researchers report progress on two top eye disease challenges treating advanced "dry" age-related macular degeneration, and preventing blindness in people with diabetes.
While the blood-brain barrier (BBB) protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at the Swedish medical university Karolinska Institutet now present a potential solution to the problem. The key to the BBB is a cell-type in the blood vessel walls called pericytes, and the researchers hope that their findings will one day contribute to new therapies for diseases like Alzheimer's and stroke.
Scientists at the University of East Anglia have made an important breakthrough in the way anti-cancer drugs are tested. A tumour cannot grow to a large size or spread until it has developed its own blood supply and leading research has looked for a way of halting capillary formation to stop tumours taking hold.But new findings published today in the Journal of Cell Science have shown that scientists testing such treatments may not have been studying exactly what they thought they were.
While the blood-brain barrier (BBB) protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at the Swedish medical university Karolinska Institutet now present a potential solution to the problem. The key to the BBB is a cell-type in the blood vessel walls called pericytes, and the researchers hope that their findings will one day contribute to new therapies for diseases like Alzheimer's and stroke.
A new material similar to that used by the U.S. Military to treat traumatic injuries is showing promise as the next novel treatment for bleeding ulcers, a condition that commonly affects up to 15 per cent of adults, according to Hong Kong physician Dr. James Lau.
Newer treatments for age-related macular degeneration (AMD)-including an intravitreous (into the eye) injection of a chemotherapy drug and use of a related compound approved for use against the eye disease-do not appear to be associated with an increased risk of cardiovascular complications or death when compared with existing therapies, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
The number of Medicare recipients undergoing treatment for retinal conditions nearly doubled between 1997 and 2007, with significant shifts in the types of procedures most commonly performed, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
Use of folic acid supplements appears to lower blood levels of the amino acid homocysteine—theorized to be a risk factor for heart and blood vessel disease—but does not appear to be associated with reduced rates of cardiovascular events, cancer or death over a five-year period, according to a meta-analysis of previously published studies in the October 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
For patients with blockages in the carotid artery that supplies blood to the brain, carotid artery stenting (a non-surgical treatment) appears to be associated with an increased risk of both short- and long-term adverse outcomes when compared with surgical treatment (carotid endarterectomy), according to a meta-analysis of previously published studies that was posted online today and will appear in the February 2011 print issue of Archives of Neurology, one of the JAMA/Archives journals.
The complication rate during pregnancy with twins is about 40%. Women with multiple pregnancies often develop pre-eclampsia, gestational diabetes, and hemorrhages during the term of their pregnancy. Joachim W Dudenhausen from the Charité Berlin University Medicine and Rolf F Maier from Magdeburg University Medical Center, investigate which risks can be minimized by close monitoring in multiple pregnancies.
A nationwide gathering of sudden cardiac arrest (SCA) survivors, emergency responders and civilian rescuers will mark SCA Awareness Month with a Survivors & Heroes Celebration on Friday, October 8 at 6:00 p.m. at the Marriott City Center in Pittsburgh, Pennsylvania.
In research that one day may lead to the discovery of how to regenerate tissue damaged by heart disease, investigators at Childrens Hospital Los Angeles have identified PDGF as a key factor in the proliferation and transformation of epicardial cells, one type of cell that surrounds heart muscle and contributes to vessels.
In research that one day may lead to the discovery of how to regenerate tissue damaged by heart disease, investigators at Childrens Hospital Los Angeles have identified PDGF as a key factor in the proliferation and transformation of epicardial cells, one type of cell that surrounds heart muscle and contributes to vessels.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.